Bristol-Myers Squibb, a pharmaceutical company headquartered in New York City, received approval from U.S FDA for its Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.  Patients with EGFR mutation or ALK translocation should have disease progression on appropriate targeted therapy prior to receiving Opdivo.  This approval expands Opdivo’s indication for previously treated metastatic squamous NSCLC to include the non-squamous patient population.  Squamous and non-squamous NSCLC together represents approximately 85% to 90% of lung cancer cases.  It is a difficult to treat disease with high mortality, and patients with squamous and non-squamous NSCLC often respond differently to treatment.  Survival rates vary depending on the stage and type of the cancer and when it is diagnosed.


Original Article: